Shantani

Executive Summary

Shantani is an Indian proteome analytics firm offering high-resolution mass spectrometry, optical spectroscopy, and proteomics services tailored for biopharma product characterization, biosimilars, and vaccine development. Founded in 2020 and headquartered in Bengaluru, the company operates ISO/IEC 17025-certified laboratories and leverages a team with over two decades of experience. Shantani provides rapid, high-quality data to support regulatory submissions and product development, positioning itself as a key partner for pharmaceutical and biotech companies seeking analytical services. With a focus on precision and reliability, the firm addresses the growing demand for specialized proteomics in the biologics and biosimilars sectors, particularly in India’s expanding biopharma landscape. Shantani’s platform stage suggests it has established operational capabilities and is now scaling its client base and service offerings. The company has not disclosed total funding or valuation, indicating a private, bootstrapped or early-funded trajectory. Given the increasing complexity of biosimilar and vaccine development, Shantani’s services are likely to see sustained demand. Key growth drivers include the rise of biosimilars in emerging markets and the need for rigorous analytical characterization for regulatory approvals. However, competition from larger CROs and in-house capabilities of major pharma present challenges. Overall, Shantani appears well-positioned to capture niche proteomics opportunities, especially in the Indian and Asian markets.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a top-20 global pharma company for biosimilar characterization40% success
• Q1 2027ISO/IEC 17025 recertification or expansion to new analytical methods80% success
• Q2 2026Announcement of new laboratory capacity or facility expansion60% success